Berberine alleviates high-energy and low-protein diet-induced fatty liver hemorrhagic syndrome in laying hens: Insights from microbiome and metabolomics DOI Creative Commons
Xinyi Cheng, Yang Hu,

Jun Kuang

et al.

Poultry Science, Journal Year: 2024, Volume and Issue: 103(8), P. 103968 - 103968

Published: June 11, 2024

Berberine (BBR), a well-known quaternary ammonium alkaloid, is recognized for its ability to prevent and alleviate metabolic disorders because of anti-oxidative anti-inflammatory properties. However, the underlying mechanisms BBR mitigate fatty liver hemorrhagic syndrome (FLHS) through modulation gut microbiota their metabolism remained unclear. The results revealed that ameliorates lipid disorder in high-energy low-protein (HELP) diet-induced FLHS laying hens, as evidenced by improved function deposition liver, reduced blood lipids, expression synthesis-related factors. Moreover, alleviated HELP barrier dysfunction, increased microbial population, dysregulated ileum. reshaped HELP-perturbed microbiota, particularly declining abundance Desulfovibrio_piger elevating Bacteroides_salanitronis_DSM_18170. Meanwhile, metabolomic profiling analysis function, reducing levels hydrocinnamic acid, dehydroanonaine, leucinic acid. Furthermore, fecal transplantation (FMT) experiments BBR-enriched hepatic intestinal inflammation compared with those chicks received HELP. Collectively, our study provided evidence effectively induced reshaping homeostasis within liver-gut axis.

Language: Английский

Gut liver brain axis in diseases: the implications for therapeutic interventions DOI Creative Commons

Mengyao Yan,

Shuli Man,

Benyue Sun

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)

Published: Dec. 6, 2023

Gut-liver-brain axis is a three-way highway of information interaction system among the gastrointestinal tract, liver, and nervous systems. In past few decades, breakthrough progress has been made in gut liver brain axis, mainly through understanding its formation mechanism increasing treatment strategies. this review, we discuss various complex networks including barrier permeability, hormones, microbial metabolites, vagus nerve, neurotransmitters, immunity, toxic β-amyloid (Aβ) metabolism, epigenetic regulation gut-liver-brain axis. Some therapies containing antibiotics, probiotics, prebiotics, synbiotics, fecal microbiota transplantation (FMT), polyphenols, low FODMAP diet nanotechnology application regulate Besides, some special treatments targeting gut-liver include farnesoid X receptor (FXR) agonists, takeda G protein-coupled 5 (TGR5) glucagon-like peptide-1 (GLP-1) antagonists fibroblast growth factor 19 (FGF19) analogs. Targeting gut-brain embraces cognitive behavioral therapy (CBT), antidepressants tryptophan metabolism-related therapies. liver-brain contains Aβ future, better interactions will promote development novel preventative strategies discovery precise therapeutic targets multiple diseases.

Language: Английский

Citations

86
Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD) DOI Creative Commons
Raquel Benedé‐Ubieto, Francisco Javier Cubero, Yulia A. Nevzorova

et al.

Gut Microbes, Journal Year: 2024, Volume and Issue: 16(1)

Published: March 21, 2024

Obesity, insulin resistance (IR), and the gut microbiome intricately interplay in Metabolic-associated Steatotic Liver Disease (MASLD), previously known as Non-Alcoholic Fatty (NAFLD), a growing health concern. The complex progression of MASLD extends beyond liver, driven by "gut-liver axis," where diet, genetics, gut-liver interactions influence disease development. pathophysiology involves excessive liver fat accumulation, hepatocyte dysfunction, inflammation, fibrosis, with subsequent risk hepatocellular carcinoma (HCC). gut, tripartite barrier, mechanical, immune, microbial components, engages constant communication liver. Recent evidence links dysbiosis disrupted barriers to systemic inflammation progression. Toll-like receptors (TLRs) mediate immunological crosstalk between recognizing structures triggering immune responses. "multiple hit model" development factors like resistance, dysbiosis, genetics/environmental elements disrupting axis, leading impaired intestinal barrier function increased permeability. Clinical management strategies encompass dietary interventions, physical exercise, pharmacotherapy targeting bile acid (BA) metabolism, modulation approaches through prebiotics, probiotics, symbiotics, fecal microbiota transplantation (FMT). This review underscores microbiome, their impact on therapeutic prospects.

Language: Английский

Citations

53
The Role of Gut Dysbiosis in the Loss of Intestinal Immune Cell Functions and Viral Pathogenesis DOI Creative Commons
Farzaneh Fakharian,

Siva Thirugnanam,

David A. Welsh

et al.

Microorganisms, Journal Year: 2023, Volume and Issue: 11(7), P. 1849 - 1849

Published: July 21, 2023

The gut microbiome plays a critical role in maintaining overall health and immune function. However, dysbiosis, an imbalance composition, can have profound effects on various aspects of human health, including susceptibility to viral infections. Despite numerous studies investigating the influence infections microbiome, impact dysbiosis infection pathogenesis remains relatively understudied. clinical variability observed SARS-CoV-2 seasonal influenza infections, presence natural HIV suppressors, suggests that host-intrinsic factors, may contribute pathogenesis. has been shown host system by regulating intestinal homeostasis through interactions with cells. This review aims enhance our understanding how perturb mucosal cells, affecting response Specifically, we focus exploring between gamma delta (γδ) T cells microbes context inflammatory examine highlighting disease outcomes. Furthermore, discuss emerging evidence potential future directions for modulation therapy

Language: Английский

Citations

43
Metabolic dysfunction-associated steatotic liver disease and its link to cancer DOI

Markos Kalligeros,

Linda Henry, Zobair M. Younossi

et al.

Metabolism, Journal Year: 2024, Volume and Issue: 160, P. 156004 - 156004

Published: Aug. 24, 2024

Language: Английский

Citations

20
Interactions of non-starch polysaccharides with the gut microbiota and the effect of non-starch polysaccharides with different structures on the metabolism of the gut microbiota: A review DOI
Yujiao Sun, Jun Yao, Rui Gao

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: 296, P. 139664 - 139664

Published: Jan. 9, 2025

Language: Английский

Citations

2
Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies DOI
Muthukumaran Jayachandran, Shen Qu

Reviews in Endocrine and Metabolic Disorders, Journal Year: 2023, Volume and Issue: 24(6), P. 1189 - 1204

Published: Oct. 16, 2023

Language: Английский

Citations

31
Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions DOI Creative Commons

Gao-Xin Xu,

Wei Song, Chao Yu

et al.

Frontiers in Cell and Developmental Biology, Journal Year: 2023, Volume and Issue: 11

Published: May 16, 2023

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are emerging as the leading causes of worldwide. These conditions can lead to cirrhosis, cancer, failure, other related ailments. At present, transplantation remains sole treatment option for end-stage NASH, a rapidly growing socioeconomic burden. Kupffer cells (KCs) dominant population macrophages that reside in liver, playing crucial role innate immunity. Their primary function includes phagocytosing exogenous substances, presenting antigens, triggering immune responses. Moreover, they interact with during pathogenesis NAFLD, this crosstalk may either delay or exacerbate progression. Stimulation by endogenous signals triggers activation KCs, resulting expression various inflammatory factors chemokines, such NLRP3, TNF-α, IL-1B, IL-6, contributing cascade. In past 5 years, significant advances have been made understanding biological properties functions KCs including their interactions tissue molecules, underlying molecular mechanisms, signaling pathways, relevant therapeutic interventions. Having comprehensive these mechanisms characteristics enormous potential guiding future strategies prevention NAFLD.

Language: Английский

Citations

29
The impact of gut microbiome-targeted therapy on liver enzymes in patients with nonalcoholic fatty liver disease: an umbrella meta-analysis DOI
Ehsan Amini‐Salehi, Soheil Hassanipour, Mohammad‐Hossein Keivanlou

et al.

Nutrition Reviews, Journal Year: 2023, Volume and Issue: 82(6), P. 815 - 830

Published: Aug. 7, 2023

Abstract Context Nonalcoholic fatty liver disease (NAFLD) is considered the leading cause of chronic worldwide. To date, no confirmed medication available for treatment NAFLD. Previous studies showed promising effects gut microbiome–targeted therapies; however, results were controversial and strength evidence their clinical significance remained unclear. Objectives This umbrella study summarizes meta-analyses investigating probiotics, prebiotics, synbiotics on enzymes in NAFLD population. Data Source A comprehensive search PubMed, Scopus, Web Science, Cochrane Library databases was done up to December 20, 2022, find randomized control trials reporting microbial therapy patients with Extraction Two independent investigators extracted data characteristics meta-analyses, any discrepancies resolved by a third researcher. The AMSTAR2 checklist used evaluating quality studies. Analysis final total 15 included analysis. Results that microbiome-targeted therapies could significantly reduce levels alanine aminotransferase (ALT; effect size [ES], −10.21; 95% confidence interval [CI], −13.29, −7.14; P < 0.001), aspartate (AST; ES, −8.86; 95%CI, −11.39, −6.32; γ-glutamyltransferase (ES, −5.56; −7.92, −3.31; 0.001) subgroup analysis based intervention probiotics AST −8.69; −11.01, −6.37; ALT −9.82; −11.59, −8.05; 0.001). Synbiotics −11.40; −13.91, −8.88; −11.87; −13.80, −9.95; Prebiotics had significant −2.96; −8.12, 2.18, = 0.259; −4.69; −13.53, 4.15, 0.299, respectively). Conclusion Gut be therapeutic approach improvement hepatic damage However, more are needed better determine best bacterial strains, duration treatment, optimum dosage Systematic Review Registration PROSPERO registration no. CRD42022346998.

Language: Английский

Citations

24
Polysaccharide from Panax japonicus C.A. Mey prevents non-alcoholic fatty liver disease development based on regulating liver metabolism and gut microbiota in mice DOI
Yi Wu, Wen Yin,

Ping Hao

et al.

International Journal of Biological Macromolecules, Journal Year: 2024, Volume and Issue: 260, P. 129430 - 129430

Published: Jan. 18, 2024

Language: Английский

Citations

11
The effect of synbiotics on liver enzymes, obesity indices, blood pressure, lipid profile, and inflammation in patients with non-alcoholic fatty liver: a systematic review and meta-analysis of randomized controlled trials DOI Creative Commons
Vali Musazadeh,

Kimia Assadian,

Fatemeh Rajabi

et al.

Pharmacological Research, Journal Year: 2024, Volume and Issue: 208, P. 107398 - 107398

Published: Sept. 4, 2024

Language: Английский

Citations

10